Paratek Announces Webcast of Presentation at UBS Global Life Sciences Conference

    BOSTON, Sept. 23 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today
 announced that its Chief Executive Officer, Thomas J. Bigger, will present an
 overview of the company's strategy and research programs at the UBS Global
 Life Sciences Conference in New York next week.  Details of the presentation
 follow:
 
      Date:            Wednesday, September 29, 2004
 
      Time:            4:00 p.m. (EDT)
 
      Location:        The Grand Hyatt New York, Ballroom E
 
      Speaker:         Thomas J. Bigger, Chief Executive Officer
 
      Audio Webcast:   Available for 30 days on the Investor Relations page at
                       http://www.paratekpharm.com
 
     Mr. Bigger's presentation will review Paratek's Tetracycline ("TET") and
 Multiple Adaptational Response ("MAR") Programs, as well as the company's most
 recent efforts to exploit its compounds and their unique mechanisms of action
 in selected anti-inflammatory and neurodegenerative conditions including
 multiple sclerosis.
     A copy of the Paratek presentation will be available upon request.
 
     About Paratek Pharmaceuticals
     Paratek Pharmaceuticals, Inc. is engaged in the discovery and
 commercialization of new therapeutics that treat serious and life-threatening
 diseases, with a particular focus on the growing worldwide problem of
 antibiotic resistance.  Paratek's lead programs are advancing novel compounds
 that can circumvent or block bacterial resistance, as well as drugs that can
 prevent infection by many gram-negative bacteria by interfering with Multiple
 Adaptational Response (MAR) mechanisms in bacteria.  Out of these efforts,
 Paratek has discovered a new class of antibiotics, the aminomethylcyclines
 that target the need for new and potent antibacterials to overcome the problem
 of rapidly growing bacterial resistance.  The Company's lead antibiotic
 clinical candidate, BAY 73-7388, the first product from this class, is being
 developed in a collaborative partnership with Bayer HealthCare AG.
     Paratek is privately held and headquartered in Boston, Massachusetts, USA.
 For more information, visit Paratek's website at http://www.paratekpharm.com.
 
 

SOURCE  Paratek Pharmaceuticals, Inc.